What does UNIPHARM do?

UNIPHARM is a commercial agency in Veurne. Private Limited, started on 30 November 2007, 1 establishment.

What is the address of UNIPHARM?

The registered office of UNIPHARM is located at Slableedstraat 2E, 8630 Veurne.

Is UNIPHARM still active?

Yes. According to the CBE (30 October 2026) UNIPHARM is active, legal situation “Normale toestand”, started on 30 November 2007.

Is UNIPHARM registered on Peppol?

Yes, UNIPHARM is registered on the Peppol network with ID 0208:0893852030.

What is the enterprise number of UNIPHARM?

The enterprise number of UNIPHARM is BE0893852030.

When was UNIPHARM founded?

UNIPHARM was founded on 30 November 2007.

Who are the directors of UNIPHARM?

According to the 2025 annual accounts, the directors of UNIPHARM are: Kris BAES, Chris VANDENBERGHE, Geert DECRU, Kristiaan TRYPSTEEN.

Is UNIPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 November 2007; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did UNIPHARM make in 2025?

UNIPHARM posted a profit after taxes of € 16,816 in financial year 2025.

What is the revenue of UNIPHARM?

As a small company, UNIPHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 128,221.

How much does an employee at UNIPHARM earn?

The average wage cost per full-time employee at UNIPHARM was € 55,100 in 2025: staff costs of € 82,581 for 1.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does UNIPHARM have?

According to the 2025 annual accounts, UNIPHARM has 1.5 full-time equivalents (FTE).

UNIPHARM (Private Limited) - Veurne - BE0893852030

Dossier UNIPHARM, printed on 30 October 2026 from databakkes.be/en/0893852030/unipharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

UNIPHARM from Veurne, company number BE0893852030, closed financial year 2025 with a result of € 16,816 after tax. For that financial year UNIPHARM recorded a gross margin of € 128,221 and equity of € 369,364. Compared with financial year 2024, the result moved from € -55,588 to € 16,816. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Growing

€ 369,364

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 16,816

▲ still € 55,588 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 119,879

▲ 3% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 64,207.

People and assets in 2025

Full-time equivalents

1.5

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 82,581

▲ 9% vs 2024

€ 55,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 180,953

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 15,698

▲ 4% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 126,398 Gross margin 2022: € 126,398 First fiscal year in the series	€ 92,904 Gross margin 2023: € 92,904 ▼ 26% vs 2022 (€ 126,398) Unfavourable step	€ 57,231 Gross margin 2024: € 57,231 ▼ 38% vs 2023 (€ 92,904) Unfavourable step	€ 128,221 Gross margin 2025: € 128,221 ▲ 124% vs 2024 (€ 57,231) Favourable step	▲ 124%
Profit after taxes	€ 36,825 Profit after taxes 2022: € 36,825 First fiscal year in the series	€ -14,835 Profit after taxes 2023: € -14,835 ▼ € 51,660 vs 2022 (€ 36,825) Unfavourable step	€ -55,588 Profit after taxes 2024: € -55,588 ▼ € 40,752 vs 2023 (€ -14,835) Unfavourable step	€ 16,816 Profit after taxes 2025: € 16,816 ▲ € 72,403 vs 2024 (€ -55,588) Favourable step	▲ € 72,403
Equity	€ 457,451 Equity 2022: € 457,451 First fiscal year in the series	€ 428,713 Equity 2023: € 428,713 ▼ 6% vs 2022 (€ 457,451) Unfavourable step	€ 355,978 Equity 2024: € 355,978 ▼ 17% vs 2023 (€ 428,713) Unfavourable step	€ 369,364 Equity 2025: € 369,364 ▲ 4% vs 2024 (€ 355,978) Favourable step	▲ 4%
Total debts	€ 419,679 Total debts 2022: € 419,679 First fiscal year in the series	€ 428,306 Total debts 2023: € 428,306 ▲ 2% vs 2022 (€ 419,679) Unfavourable step	€ 383,871 Total debts 2024: € 383,871 ▼ 10% vs 2023 (€ 428,306) Favourable step	€ 346,663 Total debts 2025: € 346,663 ▼ 10% vs 2024 (€ 383,871) Favourable step	▼ 10%
Cash	€ 152,993 Cash 2022: € 152,993 First fiscal year in the series	€ 249,176 Cash 2023: € 249,176 ▲ 63% vs 2022 (€ 152,993) Favourable step	€ 116,552 Cash 2024: € 116,552 ▼ 53% vs 2023 (€ 249,176) Unfavourable step	€ 119,879 Cash 2025: € 119,879 ▲ 3% vs 2024 (€ 116,552) Favourable step	▲ 3%
Land & buildings	€ 154,197 Land & buildings 2022: € 154,197 First fiscal year in the series	€ 143,345 Land & buildings 2023: € 143,345 ▼ 7% vs 2022 (€ 154,197) Unchanged	€ 132,494 Land & buildings 2024: € 132,494 ▼ 8% vs 2023 (€ 143,345) Unchanged	€ 121,642 Land & buildings 2025: € 121,642 ▼ 8% vs 2024 (€ 132,494) Unchanged	▼ 8%
Retained profit	€ 117,815 Retained profit 2022: € 117,815 First fiscal year in the series	€ 102,979 Retained profit 2023: € 102,979 ▼ 13% vs 2022 (€ 117,815) Unfavourable step	€ 47,391 Retained profit 2024: € 47,391 ▼ 54% vs 2023 (€ 102,979) Unfavourable step	€ 64,207 Retained profit 2025: € 64,207 ▲ 35% vs 2024 (€ 47,391) Favourable step	▲ 35%
Balance sheet total	€ 877,130 Balance sheet total 2022: € 877,130 First fiscal year in the series	€ 857,019 Balance sheet total 2023: € 857,019 ▼ 2% vs 2022 (€ 877,130) Unchanged	€ 739,849 Balance sheet total 2024: € 739,849 ▼ 14% vs 2023 (€ 857,019) Unchanged	€ 716,027 Balance sheet total 2025: € 716,027 ▼ 3% vs 2024 (€ 739,849) Unchanged	▼ 3%
Employees (FTE)	1.2 Employees (FTE) 2022: 1.2 First fiscal year in the series	1.5 Employees (FTE) 2023: 1.5 ▲ 0.3 vs 2022 (1.2) Unchanged	1.5 Employees (FTE) 2024: 1.5 Unchanged (1.5) Unchanged	1.5 Employees (FTE) 2025: 1.5 Unchanged (1.5) Unchanged

Key figures of UNIPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to UNIPHARM?

What happened at UNIPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: profit of € 16,816. Source: NBB ↗
Aug 23, 2014 New establishment in Veurne. KBO
Nov 30, 2007 Start of the company according to the CBE. KBO

In short

From € 36,825 profit in 2022 to € 16,816 profit in 2025.

Paid € 12,879 in corporate taxes since 2022.

Best year ever: 2022, with € 36,825 profit.

On average € 85,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

APOTHEEK HILDE D'HOOGHE

APOTHEEK FRIEDEL VANTOMME

The stake of APOTHEEK HILDE D'HOOGHE, APOTHEEK FRIEDEL VANTOMME comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

UNIPHARM

PENTAPHARMA 20%

Behind UNIPHARM are Kris BAES, Chris VANDENBERGHE, Geert DECRU and Kristiaan TRYPSTEEN. The shares are held by APOTHEEK HILDE D'HOOGHE and APOTHEEK FRIEDEL VANTOMME. It owns 20% of PENTAPHARMA itself.

Directors

According to the 2025 annual accounts

Kris BAES

Director

Also active at: XMED, NUPHAR TECH, Nascendi, HECAM, BAES-BLANCKAERT

Chris VANDENBERGHE

Managing director

Also active at: PENTAPHARMA

Geert DECRU

Managing director

Also active at: Apotheek Omnia, OLIVINI, ROMAPHARM, O.P.S.

Kristiaan TRYPSTEEN

Director

Shareholders

APOTHEEK HILDE D'HOOGHE

APOTHEEK FRIEDEL VANTOMME

Participations

PENTAPHARMA

20%

Establishments

Establishment units

Physical locations of this company

Registered office

Slableedstraat 2E

8630 Veurne

2.233.827.153

Slableedstraat 2 box E

8630 Veurne

Active since 23 August 2014

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PENTAPHARMA same network

€ 4,509 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0893.852.030

VAT number

BE 0893.852.030

Registered office

Slableedstraat 2E, 8630 Veurne

Names & denominations

UNIPHARM

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

30 November 2007

Peppol

Active · Active since 17 Dec 2025

Activities · NACE

Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren

Detailhandel in farmaceutische producten

Vervaardiging van geneesmiddelen

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Handelsbemiddeling in de niet-gespecialiseerde groothandel

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

UNIPHARM

Financials

What happened to UNIPHARM?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions